Access EIS has invested in UK-based health technology startup MindSpire, which specializes in personalized vagus nerve stimulation to address chronic neurological conditions.
Information on the Target
MindSpire is a cutting-edge health technology company based in the UK, focused on revolutionizing the treatment of chronic neurological conditions through personalized vagus nerve stimulation. Their flagship product, Sonarta, leverages innovative non-invasive neuromodulation technology, offering a drug-free and user-friendly treatment option designed to enhance neurological health.
The company's approach targets the core of many persistent neurological issues, such as disrupted neural pathways that affect patients' quality of life. By harnessing the vagus nerve's capabilities, MindSpire aims to provide effective, real-time personalized solutions for conditions like anxiety, depression, tinnitus, and chronic pain.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the UK
The UK is grappling with a significant increase in chronic neurological disorders that severely compromise the quality of life for millions. Recent statistics reveal that approximately 28 million people endure chronic pain, 7.8 m
Similar Deals
redalpine, IQ Capital Partners, Seedcamp → DaltonTx
2025
Access EIS
invested in
MindSpire
in 2025
in a Seed Stage deal